Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, from Cedars-Sinai, discusses results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

The RTOG 0521 study randomized patients with high-risk localized prostate cancer to receive six cycles of adjuvant docetaxel with standard hormonal therapy and radiation therapy or hormonal and radiation therapy. An improvement in overall survival (OS) was detected after four years in the docetaxel arm, Sandler explains, with 5% being clinically significant.

OS in the docetaxel arm was 93% and 89% in the arm without docetaxel, Sandler says.

View more from the 2015 ASCO Annual Meeting

Videos

Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

Howard Sandler, MD, MS, FASTRO

Articles

Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate Cancer